Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
2.910
-0.010 (-0.34%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Can-Fite BioPharma Revenue
In the year 2025, Can-Fite BioPharma had annual revenue of $405.00K, down -39.91%. Can-Fite BioPharma had revenue of $203.00K in the half year ending December 31, 2025, a decrease of -42.17%.
Revenue (ttm)
$405.00K
Revenue Growth
-39.91%
P/S Ratio
15.91
Revenue / Employee
$81,000
Employees
5
Market Cap
6.44M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 405.00K | -269.00K | -39.91% |
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| Immuron | 4.99M |
| Xenetic Biosciences | 2.98M |
| CollPlant Biotechnologies | 2.37M |
| BioRestorative Therapies | 359.70K |
| Addex Therapeutics | 198.82K |
| Silo Pharma | 72.10K |
| Alaunos Therapeutics | 5.00K |
CANF News
- 4 weeks ago - Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs - GuruFocus
- 4 weeks ago - Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026 - GlobeNewsWire
- 4 weeks ago - Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient - GlobeNewsWire
- 6 weeks ago - Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment - GuruFocus
- 6 weeks ago - Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance - GlobeNewsWire
- 7 weeks ago - Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants - Nasdaq
- 7 weeks ago - Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study - Benzinga
- 7 weeks ago - Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study - GuruFocus